Silexion Therapeutics Corp — Form 8-K Summary
Business context and reporting period
The report, dated September 30, 2026, furnishes a press release announcing that the first patient was successfully dosed in the Phase 2/3 clinical trial of SIL204 for locally advanced pancreatic cancer. The supplied filing text does not include the press release itself or further trial details.
Silexion Therapeutics Corp is a Cayman Islands company. Its ordinary shares trade on Nasdaq under SLXN, and its warrants under SLXNW.
Financial performance and changes
This 8-K contains no financial statements or financial metrics. Revenue, profit, cash flow, margins, debt, liquidity, and comparable-period changes are not provided.
Outlook, risks, and filing treatment
The supplied text provides no financial guidance, outlook, management commentary, or discussion of contingencies. The press release was furnished under Item 7.01 and is not deemed filed for purposes of Exchange Act Section 18 or incorporated by reference into Securities Act filings.
Key facts for investors to verify
- Review Exhibit 99.1 for the full announcement and details of the SIL204 trial, including design, endpoints, timing, and next milestones.
- Check subsequent filings for trial updates, safety information, funding needs, or other material developments.
- Confirm the terms and potential dilution associated with the listed warrants; this filing does not discuss them beyond stating an exercise price of $15,525.00 per share.